A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

NCT04045496 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer
Colorectal Cancer
Pancreatic Ductal Carcinoma
Esophageal Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Breast Cancer
Other Solid Tumors

Interventions

DRUG: JAB-3312

Sponsor

Jacobio Pharmaceuticals Co., Ltd.